| Literature DB >> 15242682 |
Dominique Heymann1, Benjamin Ory, François Gouin, Jonathan R Green, Françoise Rédini.
Abstract
Bisphosphonates (BPs) have been used successfully for many years to reduce the skeletal complications associated with the benign and malignant bone diseases that are characterized by enhanced osteoclastic bone resorption. Until recently, it was thought that the clinical efficacy of BPs in the treatment of cancer patients with bone metastases was purely a result of the inhibition of osteoclast-mediated bone resorption. However, recent studies have demonstrated that BPs inhibit the growth, attachment and invasion of cancer cells in culture and promote their apoptosis. These results suggest that BPs are also anti-cancer agents, raising the possibility that BPs could inhibit cancer-cell colonization in visceral organs. However, results from clinical trials are conflicting, and whether BPs possess anti-cancer effects or not remains controversial.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15242682 DOI： 10.1016/j.molmed.2004.05.007
Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 11.951